Skip to main content

Advertisement

Log in

Urological cancer

Aspirin and the risk of prostate cancer mortality

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

The observational registry CaPSURE study reported that men with prostate cancer who were taking aspirin were less likely to die of prostate cancer than nonusers. This favourable effect seems to be stronger than that observed in a pooled analysis of randomized clinical trials of aspirin, and in other observational studies.

Key Points

  • In a follow-up study of patients with prostate cancer, aspirin was related to an appreciable decrease in prostate cancer mortality

  • This decrease has been related to a favourable action of aspirin on thrombosis

  • Observational studies suggest a modest decrease in prostate cancer risk among aspirin users

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Choe, K. S. et al. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J. Clin. Oncol. 30, 3540–3544 (2012).

    Article  CAS  Google Scholar 

  2. Bambace, N. M. & Holmes, C. E. The platelet contribution to cancer progression. J. Thromb. Haemost. 9, 237–249 (2011).

    Article  CAS  Google Scholar 

  3. Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11, 123–134 (2011).

    Article  CAS  Google Scholar 

  4. Camerer, E. et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104, 397–401 (2004).

    Article  CAS  Google Scholar 

  5. Cuzick, J. et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10, 501–507 (2009).

    Article  CAS  Google Scholar 

  6. Rothwell, P. M. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591–1601 (2012).

    Article  CAS  Google Scholar 

  7. Thun, M. J., Henley, S. J. & Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst. 94, 252–266 (2002).

    Article  CAS  Google Scholar 

  8. Brown, J. R. & DuBois, R. N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23, 2840–2255 (2005).

    Article  CAS  Google Scholar 

  9. Bosetti, C., Rosato, V., Gallus, S. & La Vecchia, C. Aspirin and urologic cancer risk: an update. Nat. Rev. Urol. 9, 102–110 (2012).

    Article  CAS  Google Scholar 

  10. Bosetti, C., Rosato, V., Gallus, S., Cuzick, J. & La Vecchia, C. Aspirin and cancer risk: a quantitative review to 2011. Ann. Oncol. 23, 1403–1415 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carlo La Vecchia.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

La Vecchia, C., Bosetti, C. Aspirin and the risk of prostate cancer mortality. Nat Rev Clin Oncol 9, 616–617 (2012). https://doi.org/10.1038/nrclinonc.2012.182

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.182

  • Springer Nature Limited

This article is cited by

Navigation